Table 2

Adjusted Hazard of Receiving an Allopurinol Prescription

Hazard Ratio95% CI
Eligible for allopurinol (ever)
 Not eligible1 [referent]1 [referent]
 CKD3.482.31–5.26
 Diuretic therapy2.492.10–2.94
 ≥2 Consultations for gout in 12 months3.883.22–4.68
 Tophi2.101.10–4.00
 Urolithiasis2.331.44–3.78
Age at diagnosis of gouta1.000.99–1.01
Male0.590.51–0.69
Overweight (BMI >25kg/mb)
 Not overweight (BMI ≤25kg/mb)1 [reference]1 [reference]
 Overweight1.141.02–1.27
 Not recorded0.880.74–1.04
Exposure to alcohol
 Never exposed1 [reference]1 [reference]
 Ever exposed to alcohol1.070.93–1.24
 Not recorded0.800.65–0.99
Charlson comorbidity scorea0.840.81–0.88
Number of consultations for gouta (during entire follow-up)1.051.02–1.08
Number of consultations for any reason (during entire follow-up)
 Quartile 1 (0–34)1 [reference]1 [reference]
 Quartile 2 (34–64)0.440.37–0.61
 Quartile 3 (65–119)0.200.16–0.24
 Quartile 4 (≥120)0.070.05–0.09
Time-varying covariatesc
Male1.0071.004–1.011
Number of consultations for gouta (during entire follow-up)1.0021.001–1.002
Number of consultations for any reason (during entire follow-up)
 Quartile 1 (0–34)1 [reference]1 [reference]
 Quartile 2 (34–64)1.0051.001–1.009
 Quartile 3 (65–119)1.0091.005–1.037
 Quartile 4 (≥120)1.0151.012–1.020
Eligible for allopurinol (ever)
 Not eligible1 [referent]1 [referent]
 CKD0.9900.982–0.999
 Diuretic therapy0.9910.988–0.994
 ≥2 consultations for gout in 12 mo0.9850.980–0.989
 Tophi0.9940.979–1.008
 Urolithiasis0.9900.982–0.999
  • ACR = American College of Rheumatology; BMI = body mass index; CKD = chronic kidney disease; EULAR = European League Against Rheumatism.

  • Note: Model is adjusted for all listed variables and clustering by practice.

  • a Denotes a continuous variable.

  • b Eligibility according to the EULAR and ACR guidelines.5,6